SAN DIEGO, March 30 /PRNewswire-FirstCall/ -- Protein Polymer
Technologies, Inc. (OTC Bulletin Board: PPTI), today announced the expansion
of its license agreement with Genencor International, Inc. (Nasdaq: GCOR), and
receipt of an associated payment.  The license agreement was initially
established in December 2000, granting Genencor worldwide exclusive rights to
industrial applications of PPTI's proprietary protein polymer design and
production technology.  Under the amended agreement, the licensed rights have
been expanded to include personal care product applications.  PPTI continues
to retain all rights to its technology for use in the development and
commercialization of medical products.  The payment received, and additional
annual payments through 2010, are in consideration for the amended license
rights.  Royalties will also be payable on sales of products.
    Genencor International is a world leader in the development and
manufacture of industrial enzymes and other biotechnology products.  Protein
Polymer Technologies, whose internal product focus is primarily medical, holds
the fundamental patents on the design and development of de novo proteins that
in form are highly repetitive polymers with unique physical and biological
properties.  "Our expanded agreement with the additional payments reflects not
only Genencor's progress towards commercial products based on our technology,
but also our progress in realizing returns on the full breadth of our
technology," said PPTI's Chief Executive Officer, J. Thomas Parmeter.

    Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing products to improve medical and surgical outcomes.  From its
inception in 1988, PPTI has been a pioneer in protein design and synthesis,
developing an extensive portfolio of proprietary biomaterials.  These
genetically engineered biomaterials are high molecular weight proteins,
processed into products with physical and biological characteristics tailored
to specific clinical performance requirements.  Targeted products include
urethral bulking agents for the treatment of stress urinary incontinence,
dermal augmentation products for cosmetic and reconstructive surgery, surgical
adhesives and sealants, scaffolds for wound healing and tissue engineering,
and depots for local drug delivery.  To date, PPTI has been issued twenty-five
U.S. patents on its core technology with corresponding issued and pending
patents in key international markets.

    This press release contains forward-looking statements that are based on
management's views and expectations.  Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences.  Risks associated with the Company's
activities include raising adequate capital to continue operations scientific
and product development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding, regulatory testing
and approvals, and manufacturing scale up.  The reader is encouraged to refer
to the Company's 2003 Annual Report Form 10-KSB and subsequent three 2004
Quarterly Reports Form 10QSB, and other recent filings with the Securities and
Exchange Commission, copies of which are available from the Company, to
further ascertain the risks associated with the above statements.

Link to this page: